Amarin Corporation plc - ADR is a biopharmaceutical company engaged in the commercial development of therapeutics to improve cardiovascular health. The company's flagship product, a prescription medication, is designed to address clinical needs in cardiovascular disease prevention, specifically targeted at reducing the risk of cardiovascular events in adult patients with elevated triglyceride levels. Amarin is actively involved in scientific innovation and clinical research, focusing on exploring the potential of lipid science to manage cardiovascular risk factors. Primarily operating in the healthcare and biotechnology sectors, Amarin collaborates with a network of global distributors for its flagship product's availability across various markets. The company is publicly traded in the form of American Depositary Receipts (ADRs) on the NASDAQ, allowing U.S. investors to invest in the company's shares without dealing with the complexities of foreign markets. Amarin's focus on a prevalent health issue, combined with its commitment to advancing cardiovascular care, positions it as a significant entity in the pharmaceutical industry, addressing critical global health challenges.